AGÕæÈ˹ٷ½

Franklin Financial Services (FRAF) � Insider transaction summary

EVP/CFO Mark R. Hollar filed a Form 4 for transactions on 07/25/2025:

• Option exercise (Code M): 3,000 common shares acquired at a strike price of $30.00.
• Share withholding (Code F): 2,102 shares surrendered at the market price of $42.83 to fund the cashless exercise.

After the two entries, Hollar’s direct beneficial ownership stands at 15,572 shares (plus 96 DRIP shares and previously reported unvested RSUs). The net result is an increase of �898 shares, signalling a modest rise in insider exposure. No derivative securities remain from the 2017 option grant; 2,927 options from a 2018 grant are still outstanding.

Insider option exercises when the market price materially exceeds the strike (â–� 43%) can indicate executive confidence and are generally viewed positively, although the partial share disposition tempers the signal. The transaction does not impact earnings or guidance but may be of interest to investors tracking insider sentiment.

Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.

Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company’s outstanding stock, indicating minimal dilution risk.

The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:

• 09 Jul 2025 â€� 200 shares â€� $602.00
• 22 May 2025 â€� 1,179 shares â€� $2,458.33
• 21 May 2025 â€� 600 shares â€� $1,262.52
• 20 May 2025 â€� 800 shares â€� $1,736.72
• 19 May 2025 â€� 1,000 shares â€� $2,226.60
• 16 May 2025 â€� 1,421 shares â€� $3,326.13

Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.

Form 4 filing � Insider transaction at Gevo (GEVO)

Executive Vice President L. Lynn Smull reported the disposition of 3,928.83 shares of Gevo common stock on 01 Jul 2025 at an average price of $1.33 per share. The shares were held in and sold through the company’s 401(k) plan; a footnote clarifies that 20.63 of those shares were liquidated between 11 Jun 2025 and 07 Jul 2025 to cover plan administrative fees.

After the transaction, Smull’s indirect 401(k) position stands at 18,098.05 shares. A separate line in the filing indicates 1,171,550 shares of direct ownership, suggesting the officer maintains a substantial equity stake. No derivative securities were reported, and the filing does not reference the use of a Rule 10b5-1 trading plan.

The sale represents a very small fraction of Smull’s total holdings and is unlikely to have a material effect on Gevo’s share float or signal a strategic outlook change. The form appears timely and complete, satisfying Section 16 reporting obligations.

iSpecimen Inc. (Nasdaq: ISPC) has filed Amendment No. 3 to its Form S-1 registration statement, signaling a forthcoming underwritten public offering of common stock and pre-funded warrants. The company plans to sell an unspecified number of shares and, for investors whose post-offering ownership would otherwise exceed 4.99% (optionally 9.99%), an equivalent number of pre-funded warrants priced at the offering price minus $0.0001 with a de-minimis $0.0001 exercise price. Both securities will be issued in a single closing on a firm-commitment basis led by WestPark Capital.

Key structural details:

• The final share count, public offering price, and gross proceeds will be determined at pricing; blanks remain in the filing.
• The company is a non-accelerated filer, smaller reporting company, and emerging growth company.
• Underwriter compensation includes customary cash fees plus up to $110,000 in reimbursable legal and out-of-pocket expenses.
• No listing is planned for the pre-funded warrants, limiting their secondary-market liquidity.

The filing emphasizes that the prospectus is preliminary, forward-looking statements are subject to risk, and no sales can occur until the SEC declares the registration effective.

iSpecimen announced significant changes to its Board of Directors on June 18, 2025. Richard J. Paolone (Chairman since February 2025) and John L. Brooks III (board member since June 2021) have resigned from the Board, effective immediately. Neither resignation involved disagreements with the company's operations, policies, or practices.

The Board appointed Anthony Lau as a new director on June 20, 2025. Lau brings significant experience as:

• CEO and CFO of Remington Resources (CSE-listed company) since 2021
• Expert in corporate governance and public company compliance
• Engineering professional in oil and gas infrastructure since 2014

Following these changes, the Board committees were restructured:

• Audit Committee: Lau (Chair), Dhaliwal, Yang
• Compensation Committee: Yang (Chair), Lau, Dhaliwal
• Nominating and Corporate Governance Committee: Dhaliwal (Chair), Yang, Lau